Glancy Binkow & Goldberg LLP Announces Continued Investigation Of ISTA Pharmaceuticals, Inc.

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the Board of Directors of ISTA Pharmaceuticals, Inc. (“ISTA” or the “Company”) (NASDAQ: ISTA) related to the proposed acquisition of the Company by Bausch & Lomb. The transaction is valued at approximately $500 million or $9.10 per share.

This investigation concerns whether the Board of Directors of ISTA breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Its share price has skyrocketed from $3.89 on December 15, 2011 to $8.30 on March 23, 2012. Further, at least one analyst has set a target price for the Company’s stock at $12.00 per share.

If you are a shareholder of ISTA, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by email to shareholders@glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Copyright Business Wire 2010

If you liked this article you might like

Stocks to Watch: Opnext, Ista (Update 1)

Apollo, Opnext: After-Hours Trading (Update 1)

10 Small-Cap Stocks Poised to Rise, History Shows (Update2)

Valeant Pulls Ista Pharma Takeout Bid

Stocks End Higher on Global Data